Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3

I tend to jump to this section these days - Unfortunately think we might need to raise next year even with R&D rebate, If we wish to retain a buffer. I hope we wait to mid 2024 when armed with interim efficacy readouts. Hoping next cap raise will be much higher than the last 17c raise.

They’ve started historical studies with 1 patient finished screening. Not much new news, sadly delay of key clinic milestones, now confirmed to be shifted right to early next year due to IND being Q4; not sure if approval expected then too.